Down regulation of protein kinase C during growth enhancement induced by interleukin-6 on a human myeloma cell line, KMS-11

• Published in: Cancer letters 1996-10, Vol.107 (1), p.131-136
• Main Authors: Shirato, Lisa, Otsuki, Takemi, Yamada, Osamu, Namba, Masayoshi, Nakajima, Hiroshi, Nozawa, Yoshinori, Ueki, Ayako, Yawata, Yoshihito
• Format: Article
• Language: English
• Subjects: Biological and medical sciences; Cell Division - drug effects; Down-Regulation; Hematologic and hematopoietic diseases; Humans; Interleukin-6; Interleukin-6 - pharmacology; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Medical sciences; Multiple myeloma; Multiple Myeloma - enzymology; Multiple Myeloma - pathology; Protein kinase C; Protein Kinase C - drug effects; Protein Kinase C - metabolism; Recombinant Proteins - pharmacology; Tumor Cells, Cultured
• ISSN: 0304-3835; 1872-7980
• DOI: 10.1016/0304-3835(96)04381-9

Interleukin-6 (IL-6) is one of the most important growth factors for myeloma cells. We examined the effect of recombinant IL-6 on the proliferation of five human myeloma cell lines, which were independently established AT Kawasaki Medical School. Only the KMS-11 cell line among these five lines showed growth enhancement induced by IL-6. Based on the results, a possible contribution of Ca 2+-phospholipid-dependent protein kinase C (PKC) to the signal transduction in KMS-11 cells during growth enhancement was studied, since PKC may play an important role in malignant transformation or cell proliferation induced by some growth factors, such as IL-6. When exogenous IL-6 was added to KMS-11 culture, we observed (1) reduction of total PKC activity, and (2) translocation of PKC activity from its cytosol fraction to the membrane fraction. These findings may indicate that down regulation of PKC occurred during the myeloma cell proliferation induced by IL-6. However, IL-6 does not appear to be involved in cell proliferation and differentiation in the other cell lines studied.